This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lee JW , Parameswaran J , Sandoval-Schaefer T , Eoh KJ , Yang DH , Zhu F , Mehra R , Sharma R , Gaffney SG , Perry EB , Townsend JP , Serebriiskii IG , Golemis EA , Issaeva N , Yarbrough WG , Koo JS , Burtness BA
Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck
Clin Cancer Res. 2019 Jun 1;25(11) :3430-3442
PMID: 30755439 PMCID: PMC6548643 URL: https://www.ncbi.nlm.nih.gov/pubmed/30755439
AbstractPURPOSE: Human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC) commonly bear disruptive mutations in TP53, resulting in treatment resistance. In these patients, direct targeting of p53 has not been successful, but synthetic lethal approaches have promise. Although Aurora A kinase (AURKA) is overexpressed and an oncogenic driver, its inhibition has only modest clinical effects in HPV-negative HNSCC. We explored a novel combination of AURKA and WEE1 inhibition to overcome intrinsic resistance to AURKA inhibition. EXPERIMENTAL DESIGN: AURKA protein expression was determined by fluorescence-based automated quantitative analysis of patient specimens and correlated with survival. We evaluated treatment with the AURKA inhibitor alisertib (MLN8237) and the WEE1 inhibitor adavosertib (AZD1775), alone or in combination, using in vitro and in vivo HNSCC models. RESULTS: Elevated nuclear AURKA correlated with worse survival among p16(-) HNSCC patients. Alisertib caused spindle defects, G2/M arrest and inhibitory CDK1 phosphorylation, and cytostasis in TP53 mutant HNSCC FaDu and UNC7 cells. Addition of adavosertib to alisertib instead triggered mitotic entry and mitotic catastrophe. Moreover, in FaDu and Detroit 562 xenografts, this combination demonstrated synergistic effects on tumor growth and extended overall survival compared to either vehicle or single agent treatment. CONCLUSIONS: Combinatorial treatment with adavosertib and alisertib leads to synergistic antitumor effects in in vitro and in vivo HNSCC models. These findings suggest a novel rational combination, providing a promising therapeutic avenue for TP53-mutated cancers.
NotesLee, Jong Woo Parameswaran, Janaki Sandoval-Schaefer, Teresa Eoh, Kyung Jin Yang, Dong-Hua Zhu, Fang Mehra, Ranee Sharma, Roshan Gaffney, Stephen G ORCID: https://orcid.org/0000-0002-5490-2945 Perry, Elizabeth B Townsend, Jeffrey P ORCID: https://orcid.org/0000-0002-9890-3907 Serebriiskii, Ilya G Golemis, Erica A ORCID: https://orcid.org/0000-0003-3618-3673 Issaeva, Natalia Yarbrough, Wendell G Koo, Ja Seok Burtness, Barbara A Journal Article United States Clin Cancer Res. 2019 Feb 12. pii: 1078-0432.CCR-18-0440. doi: 10.1158/1078-0432.CCR-18-0440.